Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 45/100

Failure Rate

0.0%

0 terminated/withdrawn out of 4 trials

Success Rate

100.0%

+13.5% vs industry average

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

0%

0 of 3 completed trials have results

Key Signals

Enrollment Performance

Analytics

Phase 1
4(100.0%)
4Total
Phase 1(4)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (4)

Showing 4 of 4 trials
NCT03417921Phase 1Suspended

A Study of ABTL0812 in Pancreatic Cancer

Role: lead

NCT04431258Phase 1Completed

ABTL0812 in Combination With FOLFIRINOX for First-line Treatment of Metastatic Pancreatic Study

Role: lead

NCT03366480Phase 1Completed

A Study to Assess the Efficacy and Safety of ABTL0812

Role: lead

NCT02201823Phase 1Completed

Phase I/Ib Clinical Trial of ABTL0812 in Advanced Cancer Patients

Role: lead

All 4 trials loaded